Precision Diagnostics

Introducing Intercept PCR™

Improve the efficiency of patient care and discover actionable insights via an integrated informatics platform. intercept PCR™ delivers a novel clinician dashboard for real time surveillance and trends across diagnostic testing modalities.

Enhanced Antimicrobial Stewardship

intercept PCR™ is the only precision medicine informatics platform for molecular diagnostics that uniquely integrates clinical and diagnostic data, enabling clinicians to gain insights, make decisions, and improve care and outcomes.

Traditional culture-based methods for detection lack sensitivity to properly diagnose urinary tract infections (UTIs) in a timely manner. Moreover, culture plating methods can require 24-48 hours in addition to antimicrobial sensitivity analyses. Now with UriCept Dx, detection of microbial interactions in UTI cases can be conducted in a matter of hours, with results shown to be more accurate in 25% or more of cases than standard culture procedures.

Bacterial vaginosis (BV) is the most common gynecological infection within the United States and affects more than 29% of women in their lifetime. This infection impacts the vaginal microbiome, shifting the dynamic of the vaginal flora leading to an increased risk of sexually transmitted infections in both symptomatic and asymptomatic patients. Conventional methods of diagnosis require bacterial culture and staining practices, as well as a specialized technician to subjectively assess samples. This time-consuming process greatly reduces the flexibility of clinical utility. Origyn Dx, our Women’s Health diagnostic tool, can assist clinicians in diagnosis of BV in record time for proper timely treatment.

A multitude of bacterial infections within the respiratory system can significantly affect short-term and long-term health. Due to the increase of antibiotic resistant respiratory tract infection strains, rapid detection methods may slow down the progression of symptoms associated with dire patient outcomes. Pneuma Dx utilizes the RT-PCR protocol to quickly assess and provide appropriate antibiotic recommendations to address the rise of severity of escalating cases. Advancements from a variety of researchers has led to the development of highly specific assays shown to express 100% specificity, greatly improving clinical care.

With the prevalence of research supporting the fundamental importance of the gut microbiome in digestive and general health, understanding the dynamic play and balance of microbes within the gastrointestinal system continues to be an important field of medicine. Because of the complex interactions between microbes, the slightest disruption can cause a pathogenic bacterial population to colonize and thrive. As the nature of the gut microbiome is to comprise of a diverse system of bacteria, many enteric pathogenic microbes may be responsible infectious gastroenteritis. Assyst Dx, our advanced clinical diagnostic tool, can accurately detect a wide variety of harmful microbes with superior sensitivity to traditional culture methods.

Exposed wounds are highly susceptible to a variety of environmental and microbial pathogens that can delay wound healing and increase the risk of infection. In addition, chronic wounds can cause severe disability and increase the risk of morbidity to patients. Properly diagnosing infectious agents can promote the longevity and healing potential of a patient, greatly improving their quality of life. With Abraze Dx, our innovative RT-PCR technology can get to the root of the infection and precisely ascertain the organisms involved with a turnaround time of only 4-6 hours. This inexpensive and rapid approach can greatly improve the detection of infectious microorganisms from wounds.


Improve the efficiency of patient care and discover actionable insights via an integrated informatics platform. intercept PCR™ delivers a novel clinician dashboard for real time surveillance and trends across diagnostic testing modalities.

  • Molecular diagnostic results in < 24 hours
  • ZPrecision antibiotic resistance markers
  • iAntibiotic prescribing based upon objective data and analytics
  • A laboratory empowering providers to lower costs and improve outcomes
  • Faster, smarter and actionable clinical data

It’s About Time

Integrity Laboratories understands that it’s about time. Antibiotic resistance is one of the biggest challenges facing our healthcare system. Diagnostic delays, as a result of standard practices in laboratory medicine, have created blind spots for providers and potential risks for patients.

Launched in 2019, Integrity Laboratories intercept PCR™ platform delivers actionable data with unmatched accuracy and speed. Providers and patients enjoy the confidence of same day and next day test results paired with antibiotic resistance markers eliminating the need for defensive administration of broad-spectrum antibiotics.

Integrity Laboratories began testing for SARS-CoV-2 (COVID-19) under Emergency Use Authorization (EUA) on March 23.

Please direct all inquiries to for immediate review.

Click Here for CDC recommendations for Identifying Monkeypox.

FDA Authorization Letter   |   FDA EUA Summary

CARES Act Statement